Gütersloh Plus
Essen und Trinken in Gütersloh
Gütersloh News und Nachrichten
Gütsel Data (Contentstatistik)
Gütsel Marketing Service (GMS)
[…] Nordisk A/S, Share repurchase programme Bagsværd, Denmark, 17 January 2022On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period […] weiterlesen …
[…] Nordisk files annual report with the SEC Bagsværd, Denmark, 2 February 2022Novo Nordisk A/S has filed its Annual Report 2021 on Form 20-F for the financial year 2021 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2021. The reports are available at the SEC's website, www. sec. gov, as well as on novonordisk. com. Shareholders may receive a hardcopy of Novo Nordisk’s completed audited financial statements free […] weiterlesen …
[…] Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 4 February 2022This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. Members of Executive Management have participated in a long-term incentive programme consisting of a one-year […] weiterlesen …
[…] Nordisk – major shareholder announcement Bagsværd, Denmark, 14 February 2022Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5. 05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to […] weiterlesen …
[…] Nordisk A/S: Share repurchase programme Bagsværd, Denmark, 21 February 2022On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 22 billion to be executed during a 12-month period […] weiterlesen …
[…] Nordisk expands research collaboration in novel delivery technologies for biologic medicines Bagsværd, Denmark, 9 March 2022Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH). Since 2015, scientists from Novo Nordisk and the laboratories of Prof. Giovanni Traverso and Prof. Robert Langer have explored novel technologies as alternatives […] weiterlesen …
[…] Nordisk – major shareholder announcement Bagsværd, Denmark, 14 March 2022Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section […] weiterlesen …
[…] bleeding after giving birth is globally a leading cause of death in new mothers [1] Bagsværd, Denmark, 22 April 2022Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an extension of the Novo Seven (eptacog alfa) label to include treatment of women suffering from severe haemorrhage after giving birth, when medications used to induce uterine contractions and reduce bleeding […] weiterlesen …
[…] Novo Nordisk A/S, Share Repurchase Programme Bagsværd, Denmark, 16 May 2022On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period […] weiterlesen …
[…] Nordisk achieves primary objectives of Onwards 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in Onwards 1 Bagsværd, Denmark, 3 June 2022Novo Nordisk today announced headline results from the main phases of Onwards 1 (52 weeks) and Onwards 6 (26 weeks) phase 3a trials with once-weekly insulin icodec. Onwards 1 (insulin naïve people with type 2 diabetes) Onwards 1 is a phase 3a, 78-week efficacy and safety treat-to-target trial […] weiterlesen …
[…] Novo Nordisk—major shareholder announcement Bagsværd, Denmark, 7 June 2022Novo Nordisk today announced that the company has been notified by Black Rock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5 percent of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to […] weiterlesen …
[…] insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in Onwards 5 phase 3a trial Bagsværd, Denmark, 3rd October 2022Novo Nordisk today announced headline results from the Onwards 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The Onwards 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus […] weiterlesen …
[…] Nordisk A/S, Share repurchase programme Bagsværd, Denmark, November 4th, 2022The execution of Novo Nordisk A/S’ overall share repurchase programme for 2022 of DKK 24 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 3. 8 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe […] weiterlesen …
[…] Nordisk invests DKK 5. 4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark Bagsværd, Denmark, November 22nd, 2022Novo Nordisk today announced plans to invest 5. 4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R & D for manufacturing of active pharmaceutical ingredients […] weiterlesen …
[…] and Novo Nordisk announce first patient dosed in clinical study with HS-001—a cell therapy designed to restore heart function in people with advanced heart failure HS 001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs). Clinical phase 1/2 study (LAPiS Study) will enrol 10 patients with advanced heart failure caused by ischaemic heart disease. Tokyo, Japan, Bagsværd, Denmark, February 10th, 2023Heartseed Inc. (Heartseed) and Novo Nordisk […] weiterlesen …
[…] Nordisk to Expand R & D Presence in Greater Boston Area Bagsværd, Denmark, March 2nd, 2023Novo Nordisk just announced plans to expand its research and development (R & D) presence in the greater Boston metro area, creating one of its largest R & D hubs outside of Denmark. This new hub, which will leverage the company’s existing presence in Lexington, Cambridge and Watertown, Massachusetts, will be home to the majority of Novo Nordisk’s US-based research and development […] weiterlesen …
